TY - JOUR
T1 - Marijuana Use in Patients With Cardiovascular Disease
T2 - JACC Review Topic of the Week
AU - DeFilippis, Ersilia M.
AU - Bajaj, Navkaranbir S.
AU - Singh, Amitoj
AU - Malloy, Rhynn
AU - Givertz, Michael M.
AU - Blankstein, Ron
AU - Bhatt, Deepak L.
AU - Vaduganathan, Muthiah
N1 - Publisher Copyright:
© 2020 American College of Cardiology Foundation
PY - 2020/1/28
Y1 - 2020/1/28
N2 - Marijuana use is increasing as more states are legalizing cannabis for both medicinal and recreational purposes. National survey data estimate that >2 million Americans with established cardiovascular diseases currently use or have used marijuana in its variety of forms, including inhalation and vaping. Cannabinoid receptors are distributed in multiple tissue beds and cells, including platelets, adipose tissue, and myocytes. Observational data suggest associations between marijuana and a broad range of adverse cardiovascular risks. Marijuana is becoming increasingly potent, and smoking marijuana carries many of the same cardiovascular health hazards as smoking tobacco. Synthetic cannabinoids have been linked to more sustained and deleterious pharmacodynamic effects. Marijuana is classified as a Schedule I substance, thus limiting its rigorous study for cardiovascular health effects. This review summarizes cardiovascular considerations related to marijuana use, pharmacological interactions, and future steps to provide clearer guidance regarding its cardiovascular safety. Screening for marijuana use is encouraged, especially in young patients presenting with cardiovascular disease.
AB - Marijuana use is increasing as more states are legalizing cannabis for both medicinal and recreational purposes. National survey data estimate that >2 million Americans with established cardiovascular diseases currently use or have used marijuana in its variety of forms, including inhalation and vaping. Cannabinoid receptors are distributed in multiple tissue beds and cells, including platelets, adipose tissue, and myocytes. Observational data suggest associations between marijuana and a broad range of adverse cardiovascular risks. Marijuana is becoming increasingly potent, and smoking marijuana carries many of the same cardiovascular health hazards as smoking tobacco. Synthetic cannabinoids have been linked to more sustained and deleterious pharmacodynamic effects. Marijuana is classified as a Schedule I substance, thus limiting its rigorous study for cardiovascular health effects. This review summarizes cardiovascular considerations related to marijuana use, pharmacological interactions, and future steps to provide clearer guidance regarding its cardiovascular safety. Screening for marijuana use is encouraged, especially in young patients presenting with cardiovascular disease.
KW - arrhythmia
KW - cannabis
KW - coronary artery disease
KW - marijuana
KW - vascular disease
UR - http://www.scopus.com/inward/record.url?scp=85077702317&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2019.11.025
DO - 10.1016/j.jacc.2019.11.025
M3 - Review article
C2 - 31976871
AN - SCOPUS:85077702317
SN - 0735-1097
VL - 75
SP - 320
EP - 332
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 3
ER -